Metal complexes of a pro-vitamin K3 analog phthiocol (2-hydroxy-3-methylnaphthalene-1,4-dione): synthesis, characterization, and anticancer activity

Harihar, Shital; Mone, Nishigandha S.; Satpute, Surekha K.; Chadar, Dattatray; Chakravarty, Debamitra; Weyhermüller, Thomas; Butcher, Raymond J.; Salunke‐Gawali, Sunita

doi:10.1039/d2dt02748h

Cited by 5 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, in a 2022 paper, Salunke-Gawali described a series of vitamin K 3 metal derivatives [124]. Mn(II), Co(II), Ni(II), Cu (II) and Zn(II) phthiocol (2-hydroxy-3-methyl-1,4naphthoquinone) complexes 77-81 (see Figure 15C) efficiently reduce the viability of MCF-7 and A549 cells and promote an apoptotic pathway.…”

Section: Metal-based Vitamin Drug Conjugatesmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Bioconjugated Transition Metal Complexes for Cancer Therapy

2023

View full text Add to dashboard Cite

The introduction of biologically relevant organic moieties in the coordination sphere of transition metal complexes has recently become a well-established strategy to increase the selectivity and biocompatibility of metallodrugs. In this review, the major advances achieved in this area of research in the last three years are described in detail. Particular attention is given to the metal complexes bearing the main biomolecules of life: carbohydrates, lipids, nucleotides, proteins and vitamins. Each paragraph summarizes the synthetic strategy employed to obtain the complexes of interest as well as the most interesting biological results obtained with these potential metallodrugs. Moreover, the structure–activity relationships observed by the different research groups are described and discussed, with the goal of suggesting to the reader the ligand/metal centre combinations that provide the most promising results in the fight against cancer. Some of the compounds examined in this review as well as other bioconjugated metal complexes published in recent decades exhibit interesting selectivity towards cancer cells over normal ones and a specific mode of action. These latter aspects are the basis of what is commonly known as anticancer target therapy.

show abstract

Section: Metal-based Vitamin Drug Conjugatesmentioning

confidence: 99%

“…In addition, mitochondria membrane potential is reduced, and the level of ROS is strongly increased by complex 79. In general, all compounds are able to induce DNA fragmentation, and notably, complex 80 inhibits topoisomerase II at 15 µM [124].…”

Section: Metal-based Vitamin Drug Conjugatesmentioning

confidence: 99%